Acute myeloblastic leukemia with maturation
| Acute myeloblastic leukemia with maturation | |
|---|---|
| Acute Myelogenous Leukemia with maturation.jpg | |
| Acute myeloblastic leukemia with maturation
| |
| Specialty | Hematology |
| Symptoms | Fatigue, pallor, bruising, bleeding, infections |
| Complications | Anemia, thrombocytopenia, neutropenia
|
| Causes | Genetic mutations |
| Risk factors | Radiation exposure, chemical exposure, genetic predisposition |
| Diagnosis | Bone marrow biopsy, blood tests
|
| Treatment | Chemotherapy, stem cell transplant
|
| Prognosis | Variable
|
Acute myeloblastic leukemia with maturation (AML-M2) is a subtype of acute myeloid leukemia (AML), a cancer of the blood and bone marrow characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.
Epidemiology[edit]
AML-M2 is one of the more common subtypes of AML, accounting for approximately 25-30% of all AML cases. It can occur at any age but is more prevalent in adults, with a median age of onset around 60 years.
Pathophysiology[edit]
AML-M2 is characterized by the presence of myeloblasts with evidence of maturation beyond the promyelocyte stage. The World Health Organization (WHO) classification of AML includes AML-M2 as a distinct entity due to its unique genetic and clinical features. The most common genetic abnormality associated with AML-M2 is the t(8;21) translocation, which results in the fusion of the RUNX1 and RUNX1T1 genes.
Clinical Presentation[edit]
Patients with AML-M2 typically present with symptoms related to bone marrow failure, including:
- Fatigue and pallor due to anemia
- Bruising and bleeding due to thrombocytopenia
- Infections due to neutropenia
Other symptoms may include fever, weight loss, and bone pain.
Diagnosis[edit]
The diagnosis of AML-M2 is based on a combination of clinical findings, laboratory tests, and bone marrow examination. Key diagnostic steps include:
- Complete blood count (CBC) showing anemia, thrombocytopenia, and leukocytosis with circulating blasts.
- Bone marrow biopsy revealing hypercellularity with a predominance of myeloblasts and evidence of maturation.
- Cytogenetic analysis to identify the t(8;21) translocation or other genetic abnormalities.
- Flow cytometry to assess the immunophenotype of the blasts.
Treatment[edit]
The treatment of AML-M2 typically involves:
- Induction chemotherapy to achieve remission, often using a combination of cytarabine and an anthracycline such as daunorubicin or idarubicin.
- Consolidation therapy to prevent relapse, which may include additional chemotherapy or hematopoietic stem cell transplantation in eligible patients.
- Targeted therapy may be considered in cases with specific genetic mutations.
Prognosis[edit]
The prognosis of AML-M2 varies depending on several factors, including the patient's age, overall health, and specific genetic abnormalities. The presence of the t(8;21) translocation is generally associated with a more favorable prognosis compared to other subtypes of AML.
Research and Future Directions[edit]
Ongoing research in AML-M2 focuses on understanding the molecular mechanisms underlying the disease, developing targeted therapies, and improving outcomes through personalized medicine approaches. Clinical trials are exploring novel agents and combination therapies to enhance treatment efficacy and reduce toxicity.
See Also[edit]
External Links[edit]
| Myeloid-related hematological malignancy | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Chromosome abnormalities | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
 | This medical article is a stub. You can help WikiMD by expanding the page. |
